Starpharma Pooled Development Ltd is an ASX listed company established in 1996 to develop a polyvalent technology based on large molecules called dendrimers. Commencing in 1992, the Biomolecular Research Institute (BRI) in Melbourne, Australia, first investigated dendrimers as protein mimics for pharmaceutical applications, before licensing the technology to Starpharma Pooled Development Ltds subsidiary company, Starpharma Pty Ltd (Starpharma).

Today, Starpharma Pooled Development Ltd has parallel investments to develop both pharmaceutical and non-pharmaceutical applications of dendrimer nanotechnology.